Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in Adult Patients With IgA Nephropathy
NCT06797518Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Feb 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of Iptacopan in immunoglobulin A nephropathy (IgAN), sponsored by Novartis. Started Feb 2025; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06797518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06797518.